Lung disease drug posts record 56.3% reduction in trial: 5 notes

Roivant’s experimental lung disease drug mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in a phase 2 trial of patients with pulmonary hypertension associated with interstitial lung disease, the highest PVR reduction reported in a randomized controlled pulmonary hypertension trial, according to a Sept. 8 news release. Here are five things to know: The post Lung disease drug posts record 56.3% reduction in trial: 5 notes appeared first on Becker&#039...